Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study

Simple item page
dc.contributor.authorAtahan, Lale
dc.contributor.authorYıldız, Ferah
dc.contributor.authorCengiz, Mustafa
dc.contributor.authorKaplan, Bünyamin
dc.contributor.authorÖzkan, Metin
dc.contributor.authorYazıcı, Gözde
dc.contributor.authorGündoğ, Mete
dc.contributor.authorHaydaroğlu, Ayfer
dc.contributor.authorKorcum, Aylin Fidan
dc.contributor.authorŞengöz, Meriç
dc.contributor.authorDinçer, Maktav
dc.contributor.authorAkmansu, Müge
dc.contributor.authorHayran, Mutlu
dc.contributor.buuauthorEngin, Kayıhan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.scopusid6701768798tr_TR
dc.date.accessioned2022-09-08T07:59:24Z
dc.date.available2022-09-08T07:59:24Z
dc.date.issued2010-06
dc.description.abstractIn this prospective study, the efficacy and safety of radiotherapy combined with zoledronic acid was evaluated. Breast cancer patients with painful bone metastases were randomized to either high- or reduced-dose radiotherapy. All patients received zoledronic acid (4 mg) every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score (VAS) for treatment satisfaction and whole-body bone scintigraphy were evaluated. No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. Our results suggest that reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid.en_US
dc.identifier.citationAtahan, L. vd. (2010). "Zoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical study". Supportive Care in Cancer, 18(6), 691-698.en_US
dc.identifier.endpage698tr_TR
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue6tr_TR
dc.identifier.pubmed19484483tr_TR
dc.identifier.scopus2-s2.0-77953621327tr_TR
dc.identifier.startpage691tr_TR
dc.identifier.urihttps://doi.org/10.1007/s00520-009-0663-x
dc.identifier.urihttps://link.springer.com/article/10.1007/s00520-009-0663-x
dc.identifier.urihttp://hdl.handle.net/11452/28552
dc.identifier.volume18tr_TR
dc.identifier.wos000277942800005tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalSupportive Care in Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone metastasisen_US
dc.subjectBreast canceren_US
dc.subjectRadiotherapyen_US
dc.subjectZoledronic aciden_US
dc.subjectIn-vitroen_US
dc.subjectSkeletal complicationsen_US
dc.subjectMultifraction radiotherapyen_US
dc.subjectBisphosphonates inhibiten_US
dc.subjectTrialen_US
dc.subjectCarcinomaen_US
dc.subjectCellsen_US
dc.subjectApoptosisen_US
dc.subjectAdhesionen_US
dc.subjectSingleen_US
dc.subjectOncologyen_US
dc.subjectHealth care sciences & servicesen_US
dc.subjectRehabilitationen_US
dc.subject.emtreeAlkaline phosphataseen_US
dc.subject.emtreeZoledronic aciden_US
dc.subject.emtreeBisphosphonic acid derivativeen_US
dc.subject.emtreeBone density conservation agenten_US
dc.subject.emtreeImidazole derivativeen_US
dc.subject.emtreeZoledronic aciden_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAlkaline phosphatase blood levelen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBone metastasisen_US
dc.subject.emtreeBone scintiscanningen_US
dc.subject.emtreeBreast canceren_US
dc.subject.emtreeCancer chemotherapyen_US
dc.subject.emtreeCancer palliative therapyen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeCancer radiotherapyen_US
dc.subject.emtreeClinical effectivenessen_US
dc.subject.emtreeClinical studyen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeDyspepsiaen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFlu like syndromeen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMultimodality cancer therapyen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeNuclear magnetic resonance imagingen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreePain assessmenten_US
dc.subject.emtreePatient safetyen_US
dc.subject.emtreePatient satisfactionen_US
dc.subject.emtreePhase 4 clinical trialen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRadiation doseen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeUrinary tract infectionen_US
dc.subject.emtreeVisual analog scaleen_US
dc.subject.emtreeWhole body scintiscanningen_US
dc.subject.emtreeBone neoplasmsen_US
dc.subject.emtreeBreast neoplasmsen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeKaplan Meier methoden_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMultimodality cancer therapyen_US
dc.subject.emtreePain measurementen_US
dc.subject.emtreePalliative therapyen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeSecondaryen_US
dc.subject.emtreeVery elderlyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshBone density conservation agentsen_US
dc.subject.meshBone neoplasmsen_US
dc.subject.meshBreast neoplasmsen_US
dc.subject.meshCombined modality therapyen_US
dc.subject.meshDiphosphonatesen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImidazolesen_US
dc.subject.meshKaplan-Meiers estimateen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPain measurementen_US
dc.subject.meshPalliative careen_US
dc.subject.meshRadiotherapy dosageen_US
dc.subject.scopusZoledronic Acid; Bone Metastasis; Bisphosphonic Acid Derivativeen_US
dc.subject.wosOncologyen_US
dc.subject.wosHealth care sciences & servicesen_US
dc.subject.wosRehabilitationen_US
dc.titleZoledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized clinical studyen_US
dc.typeArticle
dc.wos.quartileQ2 (Health care sciences & services)en_US
dc.wos.quartileQ3 (Oncology)en_US
dc.wos.quartileQ1 (Rehabilitation)en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus